[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of New Mexico\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,44,67,89,114,137,164,191,214,236,256,283,310,332,357,380,408,430,451,473,497,520,547,572,595],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100524940","ketogenic-diet-and-diabetes-demonstration-project-100524940",false,"NCT06115265","Ketogenic Diet and Diabetes Demonstration Project","KDDP","Inclusion Criteria:\n\n* Men and women ≥ 18 years old\n* BMI ≥27 kg\u002Fm2\n* Hemoglobin A1c ≥ 5.7% and\u002For fasting plasma glucose of 100-125 mg\u002FdL\n\nExclusion Criteria:\n\n* Known clinical cardiovascular disease (i.e. prior stroke, myocardial infarction, peripheral artery disease)\n* LDL cholesterol ≥ 190 mg\u002FdL\n* Triglycerides ≥ 500 mg\u002FdL\n* History of type 1 diabetes\n* History of diabetic ketoacidosis\n* Individuals requiring insulin\n* Advanced renal disease\n* Advanced liver disease\n* Terminal cancer\n* Pregnancy",true,"ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that participants in KDDP will be placed on a medically-supervised ketogenic diet, and participants in NDPP will be placed on a low fat diet.\n\nThe purpose of this study is to compare the metabolic effects of the KDDP and the NDPP on glycemic control, lipid parameters, blood pressure, heart rate, weight, and coronary artery calcium scores in individuals with either type 2 diabetes or prediabetes.",[27,28,29,30],"Type 2 Diabetes","PreDiabetes","Obesity","Ketogenic Dieting","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":35},"2023-09-05",{"date":39,"type":21},"2026-10-01",{"name":41,"class":42},"University of New Mexico","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100450036","de-identified-unmh-eeg-corpus-database-creation-with-fully-de-identified-clinical-information-100450036","NCT05140265","De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information","The Creation of a Pilot Database of EEG Recordings and de- Identified Medical Records From Patients Internally Referred Within the UNMH Comprehensive Epilepsy Center","Inclusion Criteria:\n\n* We will screen with UNMH EEG database, Nihon Kohden Neuroworkbench first. After meeting all the inclusion and exclusion criteria, we will access the Cerner Powerchart (UNMH EMR) for the rest of the clinical information.\n* 18 years old or older. If the patient's age is over 89, we will aggregated them to age 90 or older so that the patient cannot be identified. Also, all the EEG data will be de-identified and only show the year of the study performed instead of the exact study date to reduce the risk of identification. Of note, we perform over few thousands of EEG studies per year and it will be almost impossible to identify the patient based on the study year.\n\nExclusion Criteria:\n\n* Children under age of 18 years old will be excluded.\n* Mismatched patients between EEG database and EMR",{"count":52,"type":21},20000,"OBSERVATIONAL","This proposal outlines the steps required for the creation of a pilot database of EEG recordings and de-identified medical records from patients internally referred within the UNMH Comprehensive Epilepsy Center. The UNMH EEG Corpus would be the first database of its kind. Other public databases contain either patient EEG signals or medical records, but without both kinds of information, it is impossible to relate pre-treatment neurobiomarkers with post-treatment prognosis. The database will also contain information that can improve seizure localization based off of scalp and intracranial EEG, and the requisite data for the creation of algorithms that forecast seizure activity; a development that could ultimately lead to novel responsive neural stimulation procedures that suppress seizures before they begin.",[56,57,58],"Epilepsy","Status Epilepticus","Seizures","2026-06-17",{"date":61,"type":35},"2026-06-22",{"date":63,"type":35},"2021-10-11",{"date":65,"type":21},"2030-12-31",{"name":41,"class":42},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":43},"100423253","exercise-enhances-wound-healing-in-patients-with-diabetic-foot-ulcers-100423253","NCT04791449","Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers","Inclusion Criteria:\n\n* diagnosis of type 2 diabetes\n* 20 - 80 years of age\n* Ankle-Brachial Index (ABI) \\> 0.6 or Toe Pressure (TcPO2) \\> 40 mmHg\n* recent (within 12 weeks) blood glucose value between 100 - 350 mg\u002FdL\n* recent (within 12 weeks) HbA1c value \\\u003C 14 %,\n* DFU of WIfI Grade 2 or less\n* fluency in reading and speaking English or Spanish.\n\nExclusion Criteria:\n\n* inability to provide own consent\n* inability to obtain permission to participate from a medical professional\n* lack of consistent mode of transportation to UNMH\n* infection to any part of the body\n* patients that has had a transplant and\u002For is immunocompromised\n* prisoners.","20 Years","80 Years",{"count":76,"type":21},60,[24],"The overarching purpose of this study is to investigate the impact that exercise, as delivered through a medically supervised, outpatient cardiac rehabilitation program, has on the wound healing process in Type 2 diabetics having foot ulcers classified as being Wound, Ischemia, foot Infection (WIfI) stage 2 or lower. The criterion reference measure of diabetic foot ulcer wound healing is be the time required to reach the maturation phase of the wound healing cascade (wound closure without drainage).",[80],"Diabetic Foot Ulcer","2026-06-09",{"date":83,"type":35},"2026-06-11",{"date":85,"type":35},"2021-10-10",{"date":87,"type":21},"2035-05-31",{"name":41,"class":42},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":16,"sex":17,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":43},"100355499","phase-2-thinking-zinc-a-study-of-zinc-supplements-on-the-navajo-nation-100355499","NCT03908736","Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation","Thinking Zinc: A Study of Zinc Supplementation to Ameliorate Adverse Effects of Mine Waste Exposure on the Navajo Nation","Inclusion Criteria:\n\n* Men or women between the ages of 21 and 64 years of age\n* Lives in or near the participating communities of Blue Gap-Tachee Arizona or Red Water Pond Road Community New Mexico\n* Willing to provide blood and urine samples\n* Willing to attend study visits on scheduled dates\n* Willing to take a daily zinc supplement\n\nExclusion Criteria:\n\n* Women who are pregnant or nursing or women who plan to become pregnant during the course of the study.\n* Individuals who have self-reported diabetes, report that they are undergoing treatment for diabetes, or are currently taking medication for diabetes.\n* Known or suspected allergy to zinc.\n* Individuals previously diagnosed with syndromes of copper homeostasis (Menkes disease or Wilsons disease).\n* Individuals consuming zinc supplements or multivitamins and are unwilling to stop for the duration of the study.","21 Years","64 Years",{"count":99,"type":21},100,[101],"PHASE2","This is a study to assess the effect of dietary zinc supplementation to mitigate biomarkers of metal toxicity in exposed tribal populations.",[104,105],"DNA Damage","Immune System Disorder","2026-06-02",{"date":108,"type":35},"2026-06-04",{"date":110,"type":35},"2019-05-19",{"date":112,"type":21},"2027-12",{"name":41,"class":42},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":43},"100631877","phase-1-group-psilocybin-assisted-therapy-for-post-traumatic-stress-disorder-100631877","NCT07506395","Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","GPAT","Inclusion Criteria:\n\nGeneral:\n\n-T+H years of age and \\\u003C89 years of age\n\nIdentify as a member of one of the cohorts to be studied:\n\n* Veteran or first responder\n* Female survivor of sexual violence\n* Indigenous person\n* Not pregnant, planning to become pregnant, or breastfeeding; if able to become pregnant, willing to use reliable form of birth control for the duration of the study\n* If needed, ability and willingness to taper and discontinue medications that may interfere with the action of psilocybin\n* Ability to read, speak, and understand English\n* Ability and willingness to consent to the terms of the study, including attending all trial visits (most of which will occur in a group setting), preparation and\n* follow-up sessions, and completing all trial evaluations\n* Ability and willingness to swallow capsules\n\nPTSD severity:\n\n* Meet criteria for PTSD, as defined in the DSM-5\n* At screening, symptoms of moderate to severe PTSD (PCL-5 score of 34 or greater) present for at least six months\n\nExclusion Criteria:\n\n* Inability to achieve five days of abstinence from alcohol, non-prescribed opioids, methamphetamines, cocaine, benzodiazepines, or other illicit substances\n* Inability or unwillingness to remain abstinent from cannabis use for 24 hours prior to psilocybin dosing session and 12 hours after receiving the dose of psilocybin\n* Risk for clinically significant acute withdrawal from any substance that would cause safety concern on the day of dosing\n* Any medical condition that would preclude safe participation in the study, including the following, as determined by medical history review, physical examination, electrocardiogram (ECG), and clinical laboratory tests: Pregnancy\u002Fbreastfeeding\n\nCardiovascular conditions:\n\n* Uncontrolled hypertension, defined as \\>140\u002F90 mm Hg at screening or baseline or \\>145\u002F95 mm Hg on presentation for dosing day assessed on three consecutive blood pressure measurements\n* History of myocardial infarction, cardiac ischemia, congestive heart failure, clinically relevant valvular heart disease, or pulmonary hypertension; any other significant history of cardiovascular condition, based on the clinical judgment of the Trial Physician, which would make a participant unsuitable for the trial\n* ECG: Clinically significant abnormality (e.g. atrial fibrillation based on judgement of trial physician including prolonged corrected QT interval (QTc\\> 450 milliseconds (males) or \\>470 milliseconds (females)\n* Poorly controlled diabetes (HbA1c \\>8.0%; clinically significant hypoglycemia in the past 6 months)\n* Neurological conditions (e.g. epilepsy or other seizure disorder) or neurodegenerative disease (e.g., dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis.), or brain tumor that would impact participation in the trial Serious abnormalities of complete blood count or chemistry\n\n  * Severe hepatic impairment\n  * Severe renal impairment,\n  * Unstable existing thyroid disorder\n* Any of the following psychiatric conditions:\n\n  * Active suicidal ideation; history of hospitalization for suicide attempt within the 12 months prior to screening, affirmative responses to C-SSRS questions 4 or 5\n  * Confirmed diagnosis of schizophrenia or other psychotic disorder, firstdegree relative with schizophrenia\n  * Axis-II diagnosis\n* Use of psychedelics (e.g., psilocybin, mescaline, ayahuasca, DMT, LSD, MDMA, or ketamine) resulting in a discrete psychedelic experience in the past six months.\n\nUsing daily dose of psilocybin mushrooms at dose \\\u003C0.2 mg or LSD at \\\u003C20 mcg per day for \\\u003C30 days in a year (\"microdosing\") will not be an exclusion criterion.\n\nHowever, participants must agree to no further use of psychedelics during this study starting at screening.\n\n* Returning to an unsafe environment and\u002For inadequate social support-Any other condition, physical or psychological symptom, medication, or other relevant finding prior to randomization that, based on the clinical judgment of trial personnel, would make a participant unsuitable for the trial.-\n* Participation in experimental treatment for PTSD or any research studies within 30 days of screening assessment","89 Years",{"count":123,"type":21},36,[125],"PHASE1","This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.",[128],"PTSD","2026-05-20",{"date":131,"type":35},"2026-05-22",{"date":133,"type":35},"2026-05-01",{"date":135,"type":21},"2028-05-01",{"name":41,"class":42},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},"100457393","control-network-neuromodulation-to-enhance-cognitive-training-in-complex-traumatic-brain-injury-100457393","NCT05236010","Control Network Neuromodulation to Enhance Cognitive Training in Complex Traumatic Brain Injury","CONNECT-TBI","Inclusion Criteria:\n\nThere will be no gender restrictions with regard to sample inclusion. Veterans and Warfighters will be enrolled in this study if they 1) are aged 18-59; 2) have suffered a mild TBI with documented evidence of alteration in neurological functioning or loss of consciousness (LOC) which was less than 30 minutes; 3) were injured between 3 months and 5 years ago; 4) experienced less than 24 hours of post-traumatic amnesia (PTA); 5) have subjective post-TBI cognitive deficits as assessed by the NSI, with at least 1 of 4 cognitive symptoms at a score of 3 or higher (severe disturbance) or at least 2 of 4 cognitive symptoms at a score of 2 or higher (moderate disturbance). This is the target population as identified by the grant mechanism, with chronic cognitive impairments from mild traumatic brain injury. The age range of 18-59 years was selected because the investigators did not want to include developmental processes in analyses and by 18 years old, many major neurodevelopmental changes in the brain will have taken place. Using similar rationale, the investigators chose to include participants up to the age of 59 because they do not want to include advancing age-related brain changes in our analyses. They will also be 6) fluent in English, as the testing and intervention are all conducted in English; and 7) will have been on stable doses of any psychotropic medications for the past 2 months, so as to avoid confounding of results by medication effects. It is expected that the sample included in this study will reflect the demographics of the greater Albuquerque and Twin Cities metropolitan communities.\n\nExclusion Criteria:\n\nVeterans will be excluded from participation in this study if there is 1) a prior history of other neurological disease or any history of seizures beyond immediate post-traumatic seizure, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms; 2) history of psychosis, so as to reduce risk of psychiatric decompensation; 3) history of current or recent (within two years) substance\u002Falcohol dependence, to reduce confounding effects on cognition; 4) any discontinuity in skull electrical conductivity (i.e., unhealed burr holes in scalp) or artificially constructed (metal or plastic) craniotomy cover, to reduce risk of unimpeded electrical current; 5) presence of any implanted metal or electrical device (e.g. pacemaker), to reduce risk of heating during MRI, or device malfunction during neuromodulation; 6) recent medical hospitalization (within three weeks), to reduce risk of medical decompensation during the study; 7) any condition that would prevent the participant from completing the protocol, such as significant agitation; 8) appointment of a legal representative, as assessed via direct inquiry of the participant or a designated trusted other, to avoid coercion of a vulnerable population; 9) any significant hardness of hearing or blindness that would make completing the cognitive training not possible; 10) any ongoing litigation related to TBI, to prevent interference with legal proceedings; 11) any other contraindication to exposure to strong magnetic fields or MRI, such as severe claustrophobia; 12) pregnant women will be excluded as the effects of MRI and brain stimulation on developing fetuses are unknown; 13) membership in an identified vulnerable population, including minors, and prisoners, and adults unable to consent due to cognitive impairment will be excluded, as they will be unlikely to be able to complete study procedures. Prisoners will be excluded from the study to avoid coercion; 14)received a Glasgow coma scale (GCS) less than 13 or greater than 15 upon ED admission, if available in patient's records.\n\nThe investigators do not intend to include adults who are unable to consent in this study.\n\nThe investigators do not intend to include individuals who are not yet adults (infants, children, teenagers) in this study.\n\nThe investigators do not intend to include pregnant women in this study.\n\nThe investigators do not intend to include prisoners in this study.","59 Years",{"count":146,"type":21},108,[24],"The CONNECT-TBI Trial aims to develop safe, effective treatments for complex mTBI that improve cognitive functioning. Based on the compelling preliminary data generated by our study team, the objective of this study is to conduct a randomized, double-blinded, sham-controlled Phase II clinical trial of APT-3 combined with rTMS, HD-tDCS, or sham to treat cognitive control deficits in Veterans with complex mTBI and PPCS. At the Baseline Visit, participants will undergo demographic, neuropsychological, behavioral, and quality of life testing. They will also undergo structural MRI to permit modeling of their brain, resting\u002Ftask-related fMRI to identify the CCN, and pseudocontinuous arterial spin labeling (pCASL) and diffusion tensor imaging (DTI) to assess for other pathologies. They will then be randomized to 16 sessions of APT-3 with concurrent rTMS, HD-tDCS, or sham stimulation delivered to the unique functional left dorsolateral prefrontal cortex (DLPFC), a primary node of the CCN. Lastly, they will repeat all baseline tests, and report on 3- and 6-month recovery levels to establish longevity and stability of subjective benefit. Given that this individualization protocol has never been attempted for cognitive rehabilitation in military mTBI, we expect this trial will generate useful effect sizes for HD-tDCS and rTMS to be used for powering the next step, a Phase III multi-center trial.",[150],"Traumatic Brain Injury",[150,152,153,154,155],"mTBI","Prolonged Post Concussive Symptoms","Brain Stimulation","Cognitive Rehabilitation",{"date":157,"type":35},"2026-05-26",{"date":159,"type":35},"2022-01-21",{"date":161,"type":21},"2026-07-01",{"name":41,"class":42},5,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":43},"100395729","targeted-tdcs-to-enhance-speech-language-treatment-outcome-in-persons-with-chronic-post-stroke-aphasia-100395729","NCT04432883","Targeted TDCS to Enhance Speech-Language Treatment Outcome in Persons With Chronic Post-Stroke Aphasia.","Targeted Transcranial Direct Current Stimulation to Enhance Speech-Language Treatment Outcome in Persons With Chronic Post-Stroke Aphasia","AphasiatDCS","Inclusion Criteria:\n\n1. aged 25-85\n2. must be greater than 6 months post-stroke\n3. must have a diagnosis of aphasia based on impaired performance on the Western Aphasia Battery-Revised, Boston Naming Test, or during discourse production\n4. must be left-hemisphere dominant as demonstrated by aphasia onset subsequent to left hemisphere damage\n5. must be stimulable for naming\n\nExclusion Criteria:\n\n1. comorbid neurological disease.\n2. damage to the anterior right hemisphere.\n3. significant mood disorder.\n4. substance\u002Falcohol dependence or abuse within the past year\n5. presence of any implanted electrical device or contraindications to tDCS or MRI\n6. recent medical instability (within 4 weeks)\n7. pregnancy","25 Years","85 Years",{"count":175,"type":21},50,[24],"62 patients who are one year post stroke and have Aphasia as a result of that stroke will be recruited. Participants will have 4 assessment sessions and 15 treatment sessions. The TDCS will be to right Inferior Frontal Gyrus (IFG) (25 active, 25 sham) for 15 days. A combined semantic feature analysis\u002Fphonological components analysis treatment will be paired with the stimulation. Two assessment sessions will be pretreatment, 1 session immediately post-treatment, and 1 session at 3 months follow-up.",[179,180],"Stroke","Aphasia",[179,180,182,183,184],"brain stimulation","communication problems","speech and language therapy",{"date":131,"type":35},{"date":187,"type":35},"2022-10-18",{"date":189,"type":21},"2027-04-30",{"name":41,"class":42},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":96,"maxAge":74,"enrollmentInfo":198,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},"100376770","american-indian-chronic-renal-insufficiency-cohort-study-ai-cric-study-100376770","NCT04185844","American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)","AI-CRIC","Inclusion Criteria:\n\n* Glomerular Filtration Rate (GFR): eGFR of =\\>61\\\u003C80 and microalbuminuria \\> 30 or eGRF of =\\\u003C60 (no microalbuminuria required).\n\nExclusion Criteria:\n\n1. Unable or unwilling to provide informed consent\n2. life expectancy \\\u003C3 years;\n3. institutionalized subjects;\n4. End stage renal disease or renal transplant;\n5. renal cancer;\n6. myeloma;\n7. immunosuppression;\n8. Polycystic kidney disease;\n9. participation in any clinical trial,\n10. current pregnancy\n11. current incarceration.\n12. Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.",{"count":199,"type":21},500,"Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - \"CRIC 2018\" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.",[202,203,204,205],"Diabetes Mellitus","Chronic Kidney Diseases","Heart Diseases","Cardiovascular Diseases","2026-05-18",{"date":129,"type":35},{"date":209,"type":35},"2020-08-31",{"date":211,"type":21},"2028-06-30",{"name":41,"class":42},3,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":222,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":43},"100590204","cervical-ripening-balloons-for-same-day-cervical-prep-100590204","NCT06964373","Cervical Ripening Balloons for Same-Day Cervical Prep","Cervical Ripening Balloon for Same-Day Cervical Preparation for Second Trimester Termination","CRB","Inclusion Criteria:\n\n* Individuals who desire outpatient dilation and evacuation (D\\&E)\n* At least 18 years of age\n* Able and willing to consent\n* Gestational duration between 18 weeks 0 days and 19 weeks 6 days as determined by ultrasound\n* Able to read and understand English or Spanish\n* Able to obtain reliable post-procedure transportation\n* Able to observe fasting guidelines of 6 hours prior to the D\\&E procedure\n\nExclusion Criteria:\n\n* Medical conditions that require procedural management in the operating room\n* Preference for D\\&E procedure in the operating room","FEMALE",{"count":224,"type":21},70,[24],"The goal of this clinical trial is to learn if a cervical ripening balloon (Foley balloon) works to prepare the cervix before same-day outpatient dilation and evacuation (D\\&E). The main questions it aims to answer are:\n\n* Is cervical preparation with cervical ripening balloon for same-day outpatient D\\&E non-inferior to cervical preparation with osmotic dilators?\n* How feasible and safe is cervical preparation with cervical ripening balloon for same-day outpatient D\\&E?\n* How acceptable is cervical preparation with cervical ripening balloon for same-day outpatient D\\&E?\n\nParticipants will:\n\n* Have cervical preparation with cervical ripening balloon (experimental group) or osmotic dilators (usual care group)\n* Complete two surveys, one about the cervical preparation and one about the D\\&E procedure",[228],"Dilation and Evacuation",{"date":230,"type":35},"2026-05-05",{"date":232,"type":35},"2025-04-08",{"date":234,"type":21},"2026-07-31",{"name":41,"class":42},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":248,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":43},"100627817","airway-scope-vs-glidescope-for-intubation-in-obese-patients-100627817","NCT07453563","Airway Scope vs GlideScope for Intubation in Obese Patients","Comparison of GlideScope and Airway Scope for Intubating Morbidly Obese Patients: A Randomized Controlled Study","Inclusion Criteria:\n\n* Adult (age ≥18 years)\n* Body Mass Index (BMI) ≥40\n* Scheduled for surgery with general anesthesia\n\nExclusion Criteria:\n\n* Pregnancy\n* Congenital facial or airway anomalies\n* History of major neck surgery or tracheostomy\n* History of any lung diseases\u002Fconditions such as Chronic Obstructive Pulmonary Disease, lung resection, or lung cancer\n* History of cardiac failure or myocardial infarction\n* Prisoners",{"count":224,"type":21},[24],"This study compares the time required to complete intubation in obese patients (Body Mass Index 40 or greater) when using either the GlideScope or Airway Scope video laryngoscope device to help place the endotracheal tube.",[247],"Intratracheal Inbubation","NOT_YET_RECRUITING","2026-04-28",{"date":230,"type":35},{"date":252,"type":21},"2026-06",{"date":254,"type":21},"2027-03",{"name":41,"class":42},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":222,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":43},"100617030","trial-of-underwater-birth-100617030","NCT07313319","Trial of Underwater Birth","Trial of Underwater Birth: A Randomized Control Trial","TUB","Inclusion Criteria: Inclusion criteria based on A model practice template for hydrotherapy in labor and birth (2016):\n\nPrenatal inclusion criteria (to be assessed at the time of enrollment):\n\n* ≥18 years of age\n* Able to speak and understand English or Spanish\n* Singleton gestation\n* Vertex presentation\n* Able to ambulate with no mobility restrictions (i.e., no difficulty getting from seated to standing)\n* Less than class III obesity (BMI \\\u003C40 kg\u002Fm2) at initiation of prenatal care\n\nLabor inclusion criteria (to be assessed at time of admission):\n\n* Greater than 37 weeks 0 days through and less than 412 completed weeks 6 days gestation with fetus in vertex presentation\n* Normal blood pressure and normal temperature (obstetric criteria for exclusion: two blood pressures 140\u002F90 four hours apart; two fevers of over 100.4 one hour apart)\n\nExclusion Criteria: based on A model practice template for hydrotherapy in labor and birth (2016):\n\nPrenatal exclusion criteria (to be assessed at the time of enrollment):\n\n* Active infections such as HIV, Hepatitis B, Hepatitis C, HSV outbreak (on prophylaxis acceptable) (GBS positive is acceptable)\n* Pre-existing medical conditions including heart disease, uncontrolled asthma, preexisting diabetes, chronic hypertension, or activity restrictions\n* High-risk pregnancy conditions including preeclampsia, gestational hypertension, preterm gestation, multiple gestation, gestational diabetes type A2, estimated fetal weight of 5000g for non-diabetics or \\>4500 for GDM-A1, unstable substance use disorder (i.e. not in remission), placental abruption or other unexplained vaginal bleeding, previous cesarean section, fetal growth restriction (\\\u003C10th percentile), fetal anomaly, or other neonatal condition that may complicate neonatal transition to extrauterine life.\n* Existing contraindication to vaginal birth\n\nLabor exclusion criteria (to be assessed at the time of admission):\n\n* Meconium-stained amniotic fluid\n* Preterm rupture of membranes (PROM) greater than 24 hours without the start of any labor contractions (those whose have PROM greater than 24 hours but are in labor can continue to be included in the study)\n* Immediate need for operative delivery at time of admission",{"count":265,"type":21},230,[24],"Evaluate maternal perinatal outcomes in adult low-risk laboring people randomized to waterbirth compared to those randomized to birth on land.",[269],"Birth",[271,272,273,274],"waterbirth","landbirth","epidural use","birth outcomes","2026-04-22",{"date":277,"type":35},"2026-04-23",{"date":279,"type":35},"2026-04-21",{"date":281,"type":21},"2028-12",{"name":41,"class":42},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":222,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":297,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":43},"100456099","phase-2-mdma-for-co-occurring-ptsd-and-oud-after-childbirth-100456099","NCT05219175","MDMA for Co-occurring PTSD and OUD After Childbirth","MDMA-Assisted Therapy 6 to 12 Months After Childbirth for People With Co-occurring Opioid Use and Post Traumatic Stress Disorders","Inclusion Criteria:\n\n* Potential participants are eligible to enroll in the protocol if they:\n\n  1. Are at least 18 years old.\n  2. Have opioid use disorder and are using daily oral methadone of 180 mg or less, or sublingual buprenorphine (or buprenorphine with naloxone in 4:1 ratio) of 24 mg or less. Assessed as stable for at least 3 months based upon review of the University of New Mexico Milagro and FOCUS program medical records or direct communication with the participant's buprenorphine or methadone prescriber.\n  3. Are fluent in speaking and reading English. This criteria is needed as the protocol requires two therapists that have specific training and it would be very difficult to identify two therapists fluent in another language\n  4. Are able to swallow pills.\n  5. Agree to have study visits recorded, including Experimental Sessions, Independent Rater assessments by an on-site Independent Rater for CAPS-5, and non-drug therapy sessions.\n  6. Must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.\n  7. Must agree to inform the investigators within 48 hours of any medical conditions and procedures.\n  8. If able to become pregnant, must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate birth control through 10 days after the last Experimental Session. Adequate birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e., condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). Not able to become pregnant is defined as permanent sterilization or postmenopausal.\n  9. Agree to the lifestyle modifications described in Section 3.0 above:\n\n     Medical History\n  10. At Screening, meet DSM-5 criteria for current moderate to severe PTSD with a symptom duration of 6 months or longer.\n  11. At Screening, meet DSM-5 criteria for Opioid Use Disorder.\n  12. At Screening, have had PTSD symptoms for at least three months and at least moderate PTSD symptoms in the last month based on PCL-5 total score of 40 or greater.\n  13. May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines, if they pass additional screening to rule out underlying cardiovascular disease\n  14. May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation and treatment as needed.\n  15. At Baseline, have at least moderate PTSD per CAPS-5 and symptoms in the last month constituting a CAPS-5 Total Severity Score of 28 or greater\n  16. May have current mild alcohol or cannabis use disorder (meets 2 or 3 of 11 diagnostic criteria per DSM-5) or moderate alcohol or cannabis use disorder in early remission for the 3 months prior to enrollment (meets 5 of 11 diagnostic criteria per DSM-5).\n  17. May have a history of or current Diabetes Mellitus (Type 2) if additional screening measures rule out underlying cardiovascular disease, if the condition is judged to be stable on effective management, and with approval by the study physician.\n  18. May have hypothyroidism if taking adequate and stable thyroid replacement medication.\n  19. May have a history of, or current, glaucoma if approval for study participation is received from an ophthalmologist.\n\nExclusion Criteria (partial):\n\n* Potential participants are ineligible to enroll in the protocol if they:\n\n  1. Are not able to give adequate informed consent.\n  2. Prisoners will be excluded\n  3. Are likely, in the investigator's opinion and via observation during the Preparatory Period, to be re-exposed to their index trauma, lack social support, or lack a stable living situation.\n  4. Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation.\n  5. A 12 Lead EKG demonstrates QTc greater than 460 msec at time of screening for any potential participant or for the participants using methadone on an EKG obtained within 72 hours of each MDMA treatment session. An abnormal EKG may be repeated once to confirm the presence of QTc prolongation. 460 msec used as the upper acceptable limit as this study only includes women and the level of QTc that is considered abnormal is 10-20 msec longer for women.\n\n     Psychiatric History\n\n  7\\. Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment. 8. Have a history of or a current primary psychotic disorder, bipolar disorder 1 assessed via MINI and clinical interview or dissociative identity disorder assessed via structured clinical interview (SCID).\n\n  9\\. Have a current eating disorder with active purging assessed via MINI and clinical interview.\n\n  10\\. Have current major depressive disorder with psychotic features assessed via MINI.\n\n  11\\. Have a current moderate (not in early remission in the 3 months prior to enrollment based on meeting 4 or 5 of 11 diagnostic criteria per DSM-5) or severe alcohol or cannabis use disorder within the 6 months prior to enrollment (meets at least 6 of 11 diagnostic criteria per DSM-5).\n\n  12\\. Have an active illicit (other than cannabis or opioids) or prescription drug substance use disorder at any severity within 3 months prior to enrollment.\n\n  13\\. If there has been a diagnosis of moderate or severe cannabis use disorder within the last six months prior to enrollment, then the participant will need to have tapered off cannabis prior to the time of enrollment in the study and have either entered abstinence, limited cannabis use, or mild cannabis disorder. Mild cannabis use disorder or cannabis use alone are not exclusion criteria, however there can be no use in the 24 hours prior to the medication session.\n\n  14\\. Have current Personality Disorders Cluster A (paranoid, schizoid, schizotypal),) assessed via SCID-5-PD 15. Investigators will exclude potential participants with high risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, or lack of meaningful social support) 16. Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled.\n\nMedical History\n\n17\\. Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate.\n\n19\\. Have uncontrolled essential hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher assessed on three separate occasions).\n\n20\\. Have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease.\n\n21\\. Have a history of arrhythmia, other than occasional premature atrial contractions (PACs) or PVCs in the absence of ischemic heart disease, within 12 months of screening.\n\n23\\. Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n\n24\\. Require use of concomitant medications that prolong the QT\u002FQTc interval during Experimental Sessions. Refer to Protocol Section \\_12\\_\\_\\_: Concomitant Medications.\n\n25\\. Have symptomatic liver disease or have significant liver enzyme elevations. 26. Have history of hyponatremia or hyperthermia. 27. Weigh less than 48 kilograms (kg). 29. Are pregnant or are able to become pregnant and are not practicing an effective means of birth control.",{"count":291,"type":21},15,[101],"This is an open-label study of the use of MDMA Assisted Therapy for postpartum people with co-occurring Post Traumatic Stress Disorder (PTSD) and Opioid Use Disorder (OUD). The study protocol has been adapted from the Phase 3 studies sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) for PTSD. Due to the high rate of concurrence of PTSD and OUD, people with OUD may experience great benefit from the treatment of their PTSD with MDMA-assisted therapy based on the phase 2 and 3 studies for PTSD. Use of MDMA-assisted therapy in this population has the potential to be of benefit for their OUD and maternal- infant attachment.\n\nThis study will serve to explore the feasibility and safety of offering MDMA-assisted therapy for treatment of PTSD in postpartum people with opioid use disorder. The CAPs 5 (PTSD) is the primary outcome, the Timeline Follow-Back (TLFB) for opioid use is the secondary outcome and other assessments of opioid use disorder, effects on maternal-infant attachment, social connectedness and other mental health outcomes are exploratory. The study will be conducted at the University of New Mexico Health Sciences Center located in Albuquerque New Mexico. In addition to northern New Mexico being an epicenter of the current opioid use disorder epidemic in the United States there is a long-standing history of multigenerational use of illicit opioids in many communities of northern New Mexico. There are high rates of opioid use disorder on pregnancy and accompanying Neonatal Opioid Use Withdrawal Syndrome (NOWS) in Albuquerque, Santa Fe, and surrounding communities.",[295,296],"Stress Disorders, Post-Traumatic","Opioid Use Disorder",[128,296,298,299,300,301],"Addiction","MDMA","Psychedelic Assisted Therapy","Maternal Infant Bonding","2026-03-12",{"date":304,"type":35},"2026-03-16",{"date":306,"type":35},"2024-04-16",{"date":308,"type":21},"2027-11",{"name":41,"class":42},{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":43},"100476832","motivational-interviewing-at-intake-vs-intake-as-usual-on-client-engagement-in-addiction-treatment-100476832","NCT05489068","Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment","Adapting Intake Procedures to Improve Treatment Delivery in Addiction Treatment","Inclusion Criteria (client participants):\n\n* English-speaking adults seeking treatment for alcohol or other drug use at one of two outpatient addiction treatment programs\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures\n* Physically withdrawn from alcohol or other drugs\n\nInclusion Criteria (personnel participants):\n\n* English-speaking adults currently employed at one of the two outpatient addiction treatment programs\n* Provision of electronic informed consent\n\nExclusion Criteria (client participants):\n\n* Experiencing severe withdrawal symptoms\n* Actively psychotic, manic, and\u002For suicidal\n\nExclusion Criteria (personnel participants):\n\n* current position: facility owner or clinical director",{"count":318,"type":21},150,[24],"This K23 study is an effectiveness-implementation hybrid type I design to determine the effectiveness of Motivational Interviewing at Intake (MII), relative to intake-as-usual on client engagement and mechanisms of engagement among adults seeking outpatient addiction treatment. We also will obtain personnel feedback on the feasibility of implementing MII into standard practice by having personnel from the addiction treatment study sites complete implementation climate measures before Motivational Interviewing (MI) training and post-clinical trial, as well as an individual interview on implementation feasibility post-trial.",[322,323],"Substance-Related Disorders","Treatment Adherence","2026-03-05",{"date":326,"type":35},"2026-03-09",{"date":328,"type":35},"2022-03-16",{"date":330,"type":21},"2026-12-01",{"name":41,"class":42},{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":356,"locationsCount":43},"100552906","cognitive-strategies-for-optimizing-brain-health-and-managing-transgenerational-vascular-risk-factors-post-stroke-100552906","NCT06479174","Cognitive Strategies for Optimizing Brain Health And Managing Transgenerational Vascular Risk Factors Post-Stroke","Cognitive Strategies for Optimizing Brain Health And Managing Transgenerational Vascular Risk Factors Post-Stroke (CHAMPS for Transgenerational Risk)","CHAMPS-TR","Inclusion Criteria:\n\n1. primary diagnosis of acute ischemic stroke,\n2. impairment of cognitive function (score \\>1 on Quick Executive Interview - telephone screener),\n3. absence of severe aphasia (score of 0 or 1 on NIH Stroke Scale),\n4. absence of pre-stroke dementia (client report),\n5. absence of major anxiety and depressive disorder (PHQ-9, GAD-7),\n6. absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),\n7. greater than 40 years of age,\n8. having a potential family member who meets targeted family member criteria,\n9. eligible for MRI and Remote Supervised-transcranial direct current stimulation (RS-tDCS) if in CHAMPS-TR plus RS-tDCS (e.g., not pregnant; no intracranial metal implants; no skin lesions on target sites for stimulation; no severe cardiopulmonary, renal or hepatic diseases; no pacemakers; no underlying medical reason for not engaging in MRI or tDCS).\n\nThe targeted family member will be:\n\n1. a minimum of 18 years of age,\n2. biological kin of person with stroke,\n3. absence of dementia (client report),\n4. absence of major anxiety and depressive disorder (PHQ-9, GAD-7),\n5. absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),\n6. greater than 18 years of age, and\n7. having a sibling or parent who had an ischemic stroke\n\nExclusion Criteria:\n\nFor all participants:\n\n1. not English speaking, reading, and understanding, and\n2. no access to video-conference software on a computer or smart device",{"count":20,"type":21},[24],"People living with the cognitive effects of stroke are at risk for recurrent stroke and further cognitive decline. Also problematic is that stroke risk clusters in families and biological family members of people who have ischemic stroke may also be at increased risk of stroke and\u002For cognitive decline. The primary goal of this study is to test the feasibility of a virtually delivered cognitive strategy training and health coaching program to reduce vascular risk and promote brain health in persons with stroke and their biological family members.",[344],"Stroke, Ischemic",[346,347,348,349],"risk reduction","cognition","executive function","cardiometabolic conditions","2026-02-10",{"date":352,"type":35},"2026-02-11",{"date":354,"type":35},"2023-10-12",{"date":34,"type":21},{"name":41,"class":42},{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":364,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":43},"100492982","amplitude-titration-to-improve-ect-clinical-outcomes-100492982","NCT05699226","Amplitude Titration to Improve ECT Clinical Outcomes","Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial","Inclusion Criteria:\n\n* Diagnosis of major depressive disorder or bipolar II\n* Clinical indications for ECT with right unilateral electrode placement\n\nExclusion Criteria:\n\n* Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)\n* Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)\n* Current drug or alcohol use disorder (except for nicotine)\n* Contraindications to MRI.","50 Years",{"count":175,"type":21},[24],"A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT:\n\nH1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2).\n\nH2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency",[369,370,371],"Depression","ECT","Cognitive Change","2026-01-23",{"date":374,"type":35},"2026-01-26",{"date":376,"type":35},"2023-09-14",{"date":378,"type":21},"2028-01-01",{"name":41,"class":42},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":394,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":43},"100619863","opioid-adherence-and-support-through-innovative-texting-strategies-100619863","NCT07350148","Opioid Adherence and Support Through Innovative Texting Strategies","Integrating Mindfulness and mHealth Approaches for Treating Opioid Use Disorder","OASIS","Inclusion Criteria:\n\n* 18 years of age or older\n* Have a cellphone that can receive text messages\n* Have internet access to complete study surveys\n* Willing to comply with all study procedures and be available for the duration of the study\n* Within 6 months of starting or resuming to take daily methadone or buprenorphine (or suboxone\u002Fsubutex)\n* Able to understand study requirements and provide informed consent\n\nExclusion Criteria:\n\n* None",{"count":76,"type":21},[24],"The goal of this clinical trial is to examine the effects of reminder and mindfulness text messages on medication adherence and managing craving, pain, and withdrawal symptoms in people taking medications for opioid use disorder through assessment questions collected twice daily during the course of treatment. The main questions it aims to answer are:\n\n1. Do daily medication reminder text messages increase medication adherence for people taking medications for opioid use disorder?\n2. To what extent do people engage with the daily mindfulness messages?\n3. What impact does daily mindfulness text message quantity have on craving, pain, forgetfulness, and withdrawal symptoms?\n\nParticipants will:\n\n1. Receive daily medication reminder text messages for at least 24 weeks (i.e., 6 months)\n2. Receive up to 6 mindfulness messages per day for 4 weeks (i.e., 1 month)\n3. Answer daily questions twice a day during the 4 weeks of mindfulness messages\n4. Answer questions about the study when enrolling, at the end of the 4 weeks of mindfulness messages, and at 4 and 16 weeks after the end of the mindfulness messages",[392,393],"Opioid Use Disorder (OUD)","Chronic Pain",[395,396,397,398,399],"text message","medications for opioid use disorder","mHealth","mindfulness","medication adherence","2026-01-15",{"date":402,"type":35},"2026-01-20",{"date":404,"type":35},"2025-10-13",{"date":406,"type":21},"2029-03",{"name":41,"class":42},{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":43},"100554176","effects-of-multiple-session-transcranial-direct-current-stimulation-tdcs-on-behavioral-physiological-and-electrophysiological-measures-with-adults-with-autism-spectrum-disorder-asd-100554176","NCT06495684","Effects of Multiple-Session Transcranial Direct Current Stimulation (tDCS) on Behavioral, Physiological, and Electrophysiological Measures With Adults With Autism Spectrum Disorder (ASD)","Inclusion Criteria:\n\n1. Age 18-35 years\n2. Proficient in English\n3. Classification of autism or autism spectrum disorder on Autism Diagnostic Observation Scale, 2nd Edition (ADOS-2) or score of \\>= 17 on Autism Quotient (AQ)\n4. Good or corrected vision and hearing\n5. Right-handed based on the Edinburgh Handedness Inventory\n6. Score of \\>= 85 on Shipley-2\n\nExclusion Criteria\n\n1. No known loss of consciousness for \\> 5 minutes\n2. No immediate biological family members with a history of epilepsy or seizure disorder\n3. No major medical needs (e.g., neurological disorders such as a seizure disorder; long-term illness)\n4. No surgically implanted metal above the neck (example: metal pins or plates, cochlear implants, aneurysm clips, brain electrodes)\n5. No hospitalization for depression, anxiety, or substance abuse in the past 12 months\n6. No individuals who are currently pregnant\n7. No pacemakers\n8. No history of neurological disorders such as stroke, multiple sclerosis, bipolar disorder, encephalitis, epilepsy, seizure disorder, or amyotrophic lateral sclerosis","35 Years",{"count":416,"type":21},20,[24],"The purpose of this clinical trial is to investigate the effects of multiple sessions of transcranial direct current stimulation (tDCS) delivered while participants complete tasks that target social learning with high functioning adults with ASD and\u002For high traits of ASD.\n\nThe main question it aims to answer is:\n\nWhat are the effects of multiple sessions of active compared to sham tDCS, with tDCS simultaneously paired with social learning tasks, from employing a within-subject, cross-over randomized controlled trial design?\n\nParticipants will:\n\n* Complete a randomly assigned block of 5 sessions of active and a block of 5 sessions of sham tDCS, with a four-week break occurring between the two blocks.\n* Complete social learning tasks simultaneously during receipt of tDCS at each session (whether receiving active or sham tDCS).\n* Complete behavioral, physiological, and electrophysiological testing before and after each block of active or sham tDCS.\n* Complete a social validity questionnaire after completion of the study.",[420,421],"Autism Spectrum Disorder","Autism or Autistic Traits","2026-01-14",{"date":424,"type":35},"2026-01-16",{"date":426,"type":35},"2024-03-12",{"date":428,"type":21},"2027-06-30",{"name":41,"class":42},{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":16,"sex":222,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":43},"100613391","prepare-perioperative-rehabilitation-around-vaginal-prolapse-repair-surgery-for-recovery-enhancement-100613391","NCT07265973","PREPARE: Perioperative REhabilitation Around Vaginal Prolapse RepAir Surgery for Recovery Enhancement","PREPARE","Inclusion Criteria:\n\n* Subjects are ≥ 18 years of age\n* English or Spanish speaking\n* Stage 2, 3 or 4 uterovaginal or vaginal vault prolapse.\n* Patient scheduled to undergo transvaginal sacrospinous ligament suspension, uterosacral ligament suspension, or Manchester procedure at The University of New Mexico Hospital.\n\nExclusion Criteria:\n\n* Inability to speak English or Spanish\n* Currently enrolled in Pelvic floor physical therapy\n* Inability to perform the home exercises\n* Dementia\n* Inability to fill out questionnaires\n* Inability to access video via internet\n* Undergoing concomitant surgeries that involve: InterStim, bladder hydrodistension\u002Ffulguration, pelvic floor Botox, mesh excision\u002Fcomplications.",{"count":438,"type":21},92,[24],"Pelvic organ prolapse is a common problem faced by millions of patients in the United States, leading to an estimated 200,000 surgeries per year. The majority of patients in the US undergoing vaginal suspension between the ages of 60-79. Deconditioning and decreased functional status after surgery can be more pronounced in elderly populations. It is important to explore ways to improve postoperative functioning for this vulnerable population.\n\nThis research study is about how good your physical functioning is after surgery. The physical functioning we are studying consist of normal daily activities, such as walking up and down stairs. This study is for patients with pelvic organ prolapse who are getting vaginal surgery to correct the prolapse.\n\nBy doing this study, we hope to learn more about ways to improve physical functioning after vaginal prolapse repair surgery. Patients will be chosen at random to participate in or not to participate in a home daily exercise program for 6 weeks. We have participants who do not participate in the home exercise program so that we can compare their physical functioning to the participants who do exercise at home. By doing this comparison, we can find out if the home exercise program helps postoperative physical functioning.\n\nIf you are in the home exercise group, a possible benefit is to have better physical functioning after surgery. If you are not assigned to the exercise group, the benefit is being a part of a study that could potentially help other women and yourself in the future to have better physical functioning after surgery. Patients will be enrolled in teh study only if they are undergoing specific surgeries at the University of New Mexico to correct their pelvic organ prolapse.",[442],"Postoperative Physical Functioning","2025-12-18",{"date":445,"type":35},"2025-12-22",{"date":447,"type":35},"2025-11-24",{"date":449,"type":21},"2028-06-25",{"name":41,"class":42},{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":213},"100559537","opioid-and-pain-treatment-in-indigenous-communities-optic-trial-100559537","NCT06565416","Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial","Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial: Implementation of Screening and Brief Intervention","OPTIC","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* have English comprehension and proficiency\n* receiving services at one of our participating study sites\n* report current chronic pain and\u002For opioid misuse\u002Fopioid use disorder\n* self-identify as American Indian\u002FAlaska Native\n\nExclusion Criteria:\n\n* if they have a psychiatric, cognitive, or medical condition that interferes with the consenting process",{"count":460,"type":21},225,[24],"The present study seeks to examine the implementation process of culturally tailoring screening and brief intervention for both chronic pain and opioid misuse\u002Fopioid use disorder in three American Indian and Alaska Native (AI\u002FAN) serving clinics. The investigators also will assess staff perspectives on this implementation as well as a survey to understand clients at these sites who have chronic pain and opioid misuse\u002Fopioid use disorder.",[296,464,393],"Opioid Misuse","2025-11-10",{"date":467,"type":35},"2025-11-12",{"date":469,"type":35},"2023-06-01",{"date":471,"type":21},"2028-07",{"name":41,"class":42},{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":43},"100591593","wellness-alcohol-vitals-and-emotions-100591593","NCT06982443","Wellness, Alcohol, Vitals, and Emotions","Mindfulness-Based Relapse Prevention and Psychophysiological Self-Regulation","WAVE","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Meet criteria for a moderate to severe alcohol use disorder within the previous 3-months.\n3. Able to attend group meetings at the time listed on the recruitment materials.\n4. Willing to wear a sensor for the 8-week intervention period and return the sensor after the immediate follow-up.\n5. Have a phone\u002Ftablet\u002Fcomputer with internet access.\n6. Be able to comprehend and consent to study requirements in English.\n7. Have access to a valid U.S. mailing address for receiving the HRV sensors and reside in the United States.\n\nExclusion Criteria:\n\n1. Current symptoms of psychosis or mania.\n2. Have a substance use disorder requiring a higher level of care than outpatient treatment (e.g., severe alcohol use disorder requiring inpatient detoxification).\n3. Have a history of pulmonary or cardiovascular disease that interferes with sensor data collection and HRV metrics (i.e., ectopic beats, arrythmia, congenital heart disease).",{"count":482,"type":21},120,[24],"The goal of this clinical trial is to examine the effects of mindfulness based relapse prevention on self-regulation overtime and drinking in daily life through the use of wearable heart rate sensors during mindfulness groups and answering assessment questions 3 times per day during the course of treatment. The main questions that it aims to answer are:\n\n1. What changes in self-regulation as measured through heart rate variability are observed during a mindfulness intervention and how do those self-regulatory changes affect drinking after treatment?\n2. How do changes in heart rate variability affect drinking, craving, and negative affectivity in daily life?\n\nParticipants will:\n\n1. Answer questions related to their mood and drinking behaviors.\n2. Wear their sensors during an 8-week treatment period with 1 group per week.\n3. Answer questions 3 times a day during the treatment period. 4.) Return their sensors via a pre-stamped package and answer questions about their mood and drinking behaviors 3- and 6-months after the mindfulness groups end.",[486],"Alcohol Use",[488,398,489],"alcohol","harm reduction","2025-11-05",{"date":465,"type":35},{"date":493,"type":35},"2025-10-01",{"date":495,"type":21},"2029-09-01",{"name":41,"class":42},{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":506,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":43},"100536736","phase-4-particulate-vs-non-particulate-steroid-for-sacroiliac-joint-injection-100536736","NCT06268704","Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection","Particulate Versus Non-Particulate Corticosteroid in Sacroiliac Joint Injection: A Randomized Prospective Study","Inclusion Criteria:\n\n* Aged \\>18, capable of understanding and providing consent in English, capable of complying with the outcome instruments used, capable of attending all planned follow up visits\n* Unilateral low back\u002Fbuttocks pain of at least 2 weeks.\n* Patient reported 7 day average of numeric pain rating score (NPRS) low back\u002Fbuttocks pain of at least 5\u002F10 at baseline evaluation\n* Clinical diagnosis of sacroiliac joint pain as diagnosed by a board certified Physiatrist including history of low back\u002Fbuttocks pain and at least 2 positive physical exam findings (including positive fortin finger sign, pain with palpation of posterior superior iliac spine, positive FABER's test, positive Gaenslan's test, positive sacral distraction, positive thigh thrust, positive lateral compression, positive sacral thrust)\n* Patient consents to sacroiliac joint corticosteroid injection in a shared decision-making process with the treating physician.\n* 80% or more relief of index pain within first 5-15 minutes after injection\n\nExclusion Criteria:\n\n* Clinical suspicion of alternative process is greater than clinical suspicion of sacroiliac joint pain\n* Those receiving remuneration for their pain treatment (e.g., disability, worker's compensation).\n* Those involved in active litigation relevant to their pain.\n* Those unable to read English and complete the assessment instruments.\n* Those unable to attend follow up appointments\n* The patient is incarcerated.\n* History of prior sacroiliac joint fusion\n* Progressive lower extremity neurologic deficit (from active radiculopathy, unhealed radiculopathy, or neuromuscular disease)\n* Sacroiliac joint steroid injection within the prior 12 months\n* 2 Positive lumbar medial branch blocks within the past 12 months\n* Radiofrequency ablation of the lumbar spine within the past 12 months\n* Lumbar facet steroid injections within the past 12 months\n* Prior epidural steroid injection within the prior 3 months in any location within the spine.\n* Possible pregnancy or other reason that precludes the use of fluoroscopy.\n* Allergy to steroid, contrast media, or local anesthetics.\n* BMI\\>40.\n* Systemic inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, lupus).\n* Active infection or treatment of infection with antibiotics within the past 7 days.\n* Medical conditions causing significant functional disability (e.g., stroke, decompensated ---COPD, decompensated heart failure)\n* Chronic widespread pain or somatoform disorder (e.g. fibromyalgia).\n* Addictive behavior, severe clinical depression, or psychotic features.","99 Years",{"count":265,"type":21},[507],"PHASE4","This study will compare two different corticosteroids (dexamethasone and methylprednisolone) for use in sacroiliac joint injections to treat SI joint pain.",[510,511],"Sacroiliac Joint Dysfunction","Sacro-Iliac Spondylosis","2025-11-04",{"date":514,"type":35},"2025-11-06",{"date":516,"type":35},"2024-03-27",{"date":518,"type":21},"2027-05-01",{"name":41,"class":42},{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":43},"100598642","weave-nm-heart-health-and-nutrition-for-life-100598642","NCT07074145","WEAVE NM: Heart Health and Nutrition for Life","WEAVE NM Project: Heart Health and Nutrition for Life (HHNL)","WEAVE HHNL","Inclusion Criteria:\n\n* Currently a FNCH patient or are willing and able to become a FNCH patient\n* Current diagnosis of hypertension that was not onset due to pregnancy\n* Able to speak and read English or Spanish\n* Cognitively and physically able to independently understand and complete study procedures and provide written informed consent\n* Self-report at least one systolic blood pressure reading of 130 or greater in the last six months OR show a systolic blood pressure reading of 130 or greater in baseline screening\n* Live in and receive mail in Albuquerque, New Mexico\n\nExclusion Criteria:\n\n* By design, adults unable to consent, individuals not yet adults, and prisoners will not be included in this study.\n* Patients who self-report pregnancy will be automatically excluded from the study. While the investigators are not systematically screening for pregnancy throughout the study, if an individual self-reports pregnancy during the study, they will be withdrawn from study participation and offered the opportunity to re-join the study once no longer pregnant, if activities are still available, following general study procedures.\n* Individuals who are not able to complete study procedures due to mental or behavioral health conditions, incarceration, or inability to physically bear an arm cuff will also be excluded from the study.","84 Years",{"count":530,"type":21},240,[24],"WEAVE NM (Wide Engagement for Assessing Vaccine Equity in New Mexico) is a community-based research initiative working to improve health outcomes in underserved populations, with a current focus on hypertension and food justice. The project centers on the lived experiences of Native American, African American, Hispanic\u002FLatino, and Asian American residents in Albuquerque's International District and South Valley. With guidance from community voices and ongoing collaboration with local organizations, health providers, and residents, the initiative integrates cultural values, public policy, and social realities into solutions that promote equity and wellness.\n\nAs part of this work, a clinical trial is being conducted through First Nations Community HealthSource (FNCH) to evaluate a culturally tailored blood pressure intervention called Heart Health and Nutrition for Life (HHNL). The trial includes patients who receive standard hypertension care and blood pressure self-monitoring, with one group also participating in a community health worker-led educational program in their first six months of study enrollment. This curriculum addresses healthy eating, physical activity, medication adherence, stress reduction, and avoidance of alcohol and tobacco, all delivered with cultural sensitivity and community insight. After six months, the groups switch roles, allowing all participants to receive the education component.\n\nParticipants' progress is measured over a 12-month period by tracking changes in blood pressure, cholesterol, weight, blood sugar (HbA1c), and emotional well-being. The aim is to determine whether this community-supported approach improves outcomes more effectively than standard care alone with blood pressure self-monitoring. This study represents a broader effort to create long-term, community-rooted solutions to chronic health issues by addressing the social and environmental factors that influence well-being.\n\nFor individuals living in the International District or South Valley, this project offers the opportunity to take part in research that respects cultural identity and prioritizes real-world impact on health. Interested patients and families can contact their provider at FNCH to learn more about participation.",[534],"Hypertension",[534,536,537,538],"Community Health Worker","Health Education","Blood Pressure","2025-07-28",{"date":541,"type":35},"2025-07-31",{"date":543,"type":35},"2025-02-21",{"date":545,"type":21},"2027-11-30",{"name":41,"class":42},{"id":548,"slug":549,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":43},"100588377","phase-2-magnetic-resonance-analysis-of-neural-inflammatory-factors-and-external-stimulation-100588377","NCT06940609","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)","MANIFEST","Inclusion Criteria:\n\n1. aged 18-80\n2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List\n3. have \"brain fog\" or cognitive difficulties as one of the ongoing symptoms\n4. are fluent in English\n5. if taking psychotropic medications, have been on stable doses for the past month.\n\nExclusion Criteria:\n\n1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;\n2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation\n3. history of ongoing substance\u002Falcohol dependence, to reduce confounding effects on diagnosis and brain imaging\n4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS\n5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study\n6. any condition that would prevent the subject from completing the protocol\n7. appointment of a legal representative, to avoid coercion of a vulnerable population\n8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings\n9. any contraindication to MRI\n10. membership in an identified vulnerable population, including minors, pregnant women, and prisoners, so as to prevent coercion.",{"count":76,"type":21},[101],"The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are:\n\n* Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire.\n* Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, which is thought to be related to inflammation.\n\nResearchers will compare sham versus active forms of iTBS to see if the active group has greater improvement in symptoms.\n\nParticipants will complete symptom surveys, cognitive tests, and magnetic resonance imaging scans at the beginning, middle, and end of treatment.",[559,560,561,562,563],"Long COVID","Long COVID Syndrome","Long COVID-19 Syndrome","PASC","PASC Post Acute Sequelae of COVID 19","2025-07-11",{"date":566,"type":35},"2025-07-15",{"date":568,"type":35},"2025-07-07",{"date":570,"type":21},"2029-06-30",{"name":41,"class":42},{"id":573,"slug":574,"hasResults":11,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":579,"enrollmentInfo":580,"targetDuration":4,"studyType":22,"phases":582,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":43},"100587919","early-phase-1-effect-of-tirzepatide-on-markers-of-masld-in-patients-with-obesity-100587919","NCT06934642","Effect of Tirzepatide on Markers of MASLD in Patients With Obesity","Effect of Tirzepatide on Markers of MASLD in Patients With Obesity: A Pilot Study","Inclusion Criteria:\n\n* Men and women\n* Age 18-75\n* Diagnosis of MASLD based on the following criteria:\n\n  * Presence of at least 1 out of the 5 following cardiometabolic criteria:\n* BMI \\>25 kg\u002Fm2 OR waist circumference \\>94 cm (men) or 80cm (women)\n* Fasting serum glucose \\>100 mg\u002FdL OR 2-hour post-prandial glucose levels \\>140mg\u002FdL OR AbA1c \\>5.7% OR type 2 diabetes OR treatment for type 2 diabetes\n* Blood pressure \\>130\u002F85 mmHg OR specific antihypertensive drug treatment\n* Plasma triglycerides \\>150mg\u002FdL OR on lipid lowering treatment\n* Plasma HDL-cholesterol \\\u003C40mg\u002FdL (men) and \\\u003C50mg\u002FdL (women) OR on lipid lowering medication\n\n  * No other identified causes of steatosis\n  * Evidence of steatotic liver disease (hepatic steatosis identified by imaging or biopsy)\n* English speaking\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding\n* Premenopausal women not on any form of contraception\n* Reports alcohol intake \\>50g\u002Fday or 350g\u002Fweek for women and \\>60g\u002Fday or 420g\u002Fweek for men or an AUDIT score \\>8\n* Other identifiable causes of steatosis\n* Documented allergic reaction to tirzepatide or any other GLP1 RA\n* Decompensated liver disease\n* Decompensated renal disease requiring hemodialysis\n* Decompensated heart failure\n* Active malignancy\n* Prior history of pancreatitis\n* Serum triglyceride levels \\>500 mg\u002FdL\n* Personal or family history of medullary thyroid cancer or MEN2a or MEN2b\n* Concurrent use of other ant-obesity medications\n* Use of other GLP1 RAs within 3 months of study enrollment\n* Unable to obtain the medication due to cost or insurance coverage restrictions.","75 Years",{"count":581,"type":21},8,[583],"EARLY_PHASE1","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD.\n\nParticipants will be asked to:\n\n* Take tirzepatide for 12 months.\n* Come in for clinic visits every 3 months.\n* Have blood drawn at baseline, 6, and 12 months.\n* Complete a liver ultrasound at baseline and at 12 months.",[586,29],"MASLD","2025-07-10",{"date":589,"type":35},"2025-07-14",{"date":591,"type":35},"2025-06-30",{"date":593,"type":21},"2026-08",{"name":41,"class":42},{"id":596,"slug":597,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":616},"100550611","multimodal-image-analysis-and-guidance-of-neuromodulation-for-trauma-related-symptoms-100550611","NCT06449326","Multimodal Image Analysis and Guidance of Neuromodulation for Trauma-Related Symptoms","MAGNETS","Inclusion Criteria:\n\n* Veterans will be enrolled in this study if they:\n\n  1. are aged 18-80;\n  2. have a documented diagnosis of PTSD with evidence of ongoing symptoms as demonstrated by score of \"31\" or higher on the PCL-5, a measure of posttraumatic stress symptoms;\n  3. are fluent in English (as the neuropsychological testing tools used are only available in English) and\n  4. have been on stable doses of psychotropic medications for the past month.\n\nExclusion Criteria:\n\n* Veterans will be excluded from participation in this study if there is:\n\n  1. a prior history of other neurological disease beyond mild TBI, as determined by VA\u002FDoD criteria for TBI severity;\n  2. any history of seizures beyond immediate posttraumatic seizure or childhood febrile seizure, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;\n  3. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation;\n  4. active substance\u002Falcohol dependence without ongoing treatment, to reduce confounding effects on diagnosis and brain imaging;\n  5. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS;\n  6. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study;\n  7. any condition that would prevent the subject from completing the protocol;\n  8. appointment of a legal representative or inability to provide informed consent, to avoid coercion of a vulnerable population;\n  9. any ongoing litigation related to PTSD, TBI, disability determination, or service connection, to prevent interference with legal proceedings;\n  10. any contraindication to MRI;\n  11. pregnant women, so as to prevent complications;\n  12. membership in an identified vulnerable population, including minors and prisoners, so as to prevent coercion;\n  13. Cognitively impaired adults who lack capacity to consent.",{"count":603,"type":21},64,[24],"MAGNETS is a prospective, randomized, parallel-design, sham-controlled clinical trial of accelerated, functional magnetic resonance imaging (fMRI)-guided intermittent theta burst stimulation (iTBS) to the right dorsolateral prefrontal cortex (dlPFC) for chronic symptoms of posttraumatic stress disorder (PTSD) in a comorbid Veteran population.",[607],"Posttraumatic Stress Disorder","2025-07-01",{"date":610,"type":35},"2025-07-02",{"date":612,"type":35},"2024-06-01",{"date":614,"type":21},"2027-10-01",{"name":41,"class":42},2,""]